Evidence map›Paper›PMID 33869742›Full record

ArticleMolecular therapy oncolytics2021

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.

Claudia Hill, Megan Grundy, Luca Bau, Sheena Wallington, Joel Balkaran, Victor Ramos, Kerry Fisher, Len Seymour, Constantin Coussios, Robert Carlisle

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Claudia HillInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Megan GrundyInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Luca BauInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Sheena WallingtonInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Joel BalkaranInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Victor RamosGrup d'Enginyeria de Materials, Institut Quimic de Sarria, Universitat Ramon Llull, Barcelona, Spain.
Kerry FisherDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Len SeymourDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Constantin CoussiosInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
Robert CarlisleInstitute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK.
University of Oxford · GBInstitut Químic de Sarrià · ES

Funding

Cancer Research UK 29106
6 · The paper itself

Abstract

Vaccinia virus (VV) is a powerful tool for cancer treatment with the potential for tumor tropism, efficient cell-to-cell spread, rapid replication in cancer cells, and stimulation of anti-tumor immunity. It has a well-defined safety profile and is being assessed in late-stage clinical trials. However, VV clinical utility is limited by rapid bloodstream neutralization and poor penetration into tumors. These factors have often restricted its route of delivery to intratumoral or intrahepatic artery injection and may impede repeat dosing. Chemical stealthing improves the pharmacokinetics of non-enveloped viruses, but it has not yet been applied to enveloped viruses such as VV. In the present study, amphiphilic polymer was used to coat VV, leading to reduced binding of a neutralizing anti-VV antibody (81.8% of polymer-coated VV [PCVV] staining positive versus 97.1% of VV [p = 0.0038]). Attachment of anti-mucin-1 (aMUC1) targeting antibody, to give aMUC1-PCVV, enabled binding of the construct to MUC1. In high MUC1 expressing CAPAN-2 cells, infection with PCVV was reduced compared to VV, while infection was restored with aMUC1-PCVV. Pharmacokinetics of aMUC1-PCVV, PCVV, and VV were evaluated. After intravenous (i.v.) injection of 1 × 10

Indexed as

capan-2cholesterol-PEGmucin-1oncolytic virotherapypancreatic cancerpolymer coatingtargetingvaccinia virus

Identifiers

PMID33869742
PMCPMC8026752
OpenAlexW3138321053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.